These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 26468326)

  • 1. Loss of GPR3 reduces the amyloid plaque burden and improves memory in Alzheimer's disease mouse models.
    Huang Y; Skwarek-Maruszewska A; Horré K; Vandewyer E; Wolfs L; Snellinx A; Saito T; Radaelli E; Corthout N; Colombelli J; Lo AC; Van Aerschot L; Callaerts-Vegh Z; Trabzuni D; Bossers K; Verhaagen J; Ryten M; Munck S; D'Hooge R; Swaab DF; Hardy J; Saido TC; De Strooper B; Thathiah A
    Sci Transl Med; 2015 Oct; 7(309):309ra164. PubMed ID: 26468326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. G protein-biased GPR3 signaling ameliorates amyloid pathology in a preclinical Alzheimer's disease mouse model.
    Huang Y; Rafael Guimarães T; Todd N; Ferguson C; Weiss KM; Stauffer FR; McDermott B; Hurtle BT; Saito T; Saido TC; MacDonald ML; Homanics GE; Thathiah A
    Proc Natl Acad Sci U S A; 2022 Oct; 119(40):e2204828119. PubMed ID: 36161942
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of focal brain injury on beta-amyloid plaque deposition, inflammation and synapses in the APP/PS1 mouse model of Alzheimer's disease.
    Collins JM; King AE; Woodhouse A; Kirkcaldie MT; Vickers JC
    Exp Neurol; 2015 May; 267():219-29. PubMed ID: 25747037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Temporal memory deficits in Alzheimer's mouse models: rescue by genetic deletion of BACE1.
    Ohno M; Chang L; Tseng W; Oakley H; Citron M; Klein WL; Vassar R; Disterhoft JF
    Eur J Neurosci; 2006 Jan; 23(1):251-60. PubMed ID: 16420434
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The orphan G protein-coupled receptor 3 modulates amyloid-beta peptide generation in neurons.
    Thathiah A; Spittaels K; Hoffmann M; Staes M; Cohen A; Horré K; Vanbrabant M; Coun F; Baekelandt V; Delacourte A; Fischer DF; Pollet D; De Strooper B; Merchiers P
    Science; 2009 Feb; 323(5916):946-51. PubMed ID: 19213921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer's disease.
    McClean PL; Hölscher C
    Neuropharmacology; 2014 Jan; 76 Pt A():57-67. PubMed ID: 23973293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuroprotective role of MMP-9 overexpression in the brain of Alzheimer's 5xFAD mice.
    Fragkouli A; Tsilibary EC; Tzinia AK
    Neurobiol Dis; 2014 Oct; 70():179-89. PubMed ID: 25008761
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IFN-γ Production by amyloid β-specific Th1 cells promotes microglial activation and increases plaque burden in a mouse model of Alzheimer's disease.
    Browne TC; McQuillan K; McManus RM; O'Reilly JA; Mills KH; Lynch MA
    J Immunol; 2013 Mar; 190(5):2241-51. PubMed ID: 23365075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nardilysin prevents amyloid plaque formation by enhancing α-secretase activity in an Alzheimer's disease mouse model.
    Ohno M; Hiraoka Y; Lichtenthaler SF; Nishi K; Saijo S; Matsuoka T; Tomimoto H; Araki W; Takahashi R; Kita T; Kimura T; Nishi E
    Neurobiol Aging; 2014 Jan; 35(1):213-22. PubMed ID: 23954170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of accelerated senescence on learning and memory, locomotion and anxiety-like behavior in APP/PS1 mouse model of Alzheimer's disease.
    Lok K; Zhao H; Zhang C; He N; Shen H; Wang Z; Zhao W; Yin M
    J Neurol Sci; 2013 Dec; 335(1-2):145-54. PubMed ID: 24095271
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apolipoprotein D modulates amyloid pathology in APP/PS1 Alzheimer's disease mice.
    Li H; Ruberu K; Muñoz SS; Jenner AM; Spiro A; Zhao H; Rassart E; Sanchez D; Ganfornina MD; Karl T; Garner B
    Neurobiol Aging; 2015 May; 36(5):1820-33. PubMed ID: 25784209
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cannabinoid receptor 1 deficiency in a mouse model of Alzheimer's disease leads to enhanced cognitive impairment despite of a reduction in amyloid deposition.
    Stumm C; Hiebel C; Hanstein R; Purrio M; Nagel H; Conrad A; Lutz B; Behl C; Clement AB
    Neurobiol Aging; 2013 Nov; 34(11):2574-84. PubMed ID: 23838176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conditional inactivation of nicastrin restricts amyloid deposition in an Alzheimer's disease mouse model.
    Sesele K; Thanopoulou K; Paouri E; Tsefou E; Klinakis A; Georgopoulos S
    Aging Cell; 2013 Dec; 12(6):1032-40. PubMed ID: 23826707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intranasal deferoxamine reverses iron-induced memory deficits and inhibits amyloidogenic APP processing in a transgenic mouse model of Alzheimer's disease.
    Guo C; Wang T; Zheng W; Shan ZY; Teng WP; Wang ZY
    Neurobiol Aging; 2013 Feb; 34(2):562-75. PubMed ID: 22717236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progressive cognitive impairment and anxiety induction in the absence of plaque deposition in C57BL/6 inbred mice expressing transgenic amyloid precursor protein.
    Lee KW; Lee SH; Kim H; Song JS; Yang SD; Paik SG; Han PL
    J Neurosci Res; 2004 May; 76(4):572-80. PubMed ID: 15114629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cholinergic degeneration is associated with increased plaque deposition and cognitive impairment in APPswe/PS1dE9 mice.
    Laursen B; Mørk A; Plath N; Kristiansen U; Bastlund JF
    Behav Brain Res; 2013 Mar; 240():146-52. PubMed ID: 23178660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progressive age-related development of Alzheimer-like pathology in APP/PS1 mice.
    Trinchese F; Liu S; Battaglia F; Walter S; Mathews PM; Arancio O
    Ann Neurol; 2004 Jun; 55(6):801-14. PubMed ID: 15174014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 6-Methyluracil derivatives as acetylcholinesterase inhibitors for treatment of Alzheimer's disease.
    Zueva IV; Semenov VE; Mukhamedyarov MA; Lushchekina SV; Kharlamova AD; Petukhova EO; Mikhailov AS; Podyachev SN; Saifina LF; Petrov KA; Minnekhanova OA; Zobov VV; Nikolsky EE; Masson P; Reznik VS
    Int J Risk Saf Med; 2015; 27 Suppl 1():S69-71. PubMed ID: 26639718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deposition of mouse amyloid beta in human APP/PS1 double and single AD model transgenic mice.
    van Groen T; Kiliaan AJ; Kadish I
    Neurobiol Dis; 2006 Sep; 23(3):653-62. PubMed ID: 16829076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dispersible amyloid β-protein oligomers, protofibrils, and fibrils represent diffusible but not soluble aggregates: their role in neurodegeneration in amyloid precursor protein (APP) transgenic mice.
    Rijal Upadhaya A; Capetillo-Zarate E; Kosterin I; Abramowski D; Kumar S; Yamaguchi H; Walter J; Fändrich M; Staufenbiel M; Thal DR
    Neurobiol Aging; 2012 Nov; 33(11):2641-60. PubMed ID: 22305478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.